ARWR
Price
$12.64
Change
+$0.45 (+3.69%)
Updated
Apr 2, 02:34 PM (EDT)
Capitalization
1.68B
36 days until earnings call
MGNX
Price
$1.23
Change
+$0.01 (+0.82%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
80.76M
41 days until earnings call
Ad is loading...

ARWR vs MGNX

Header iconARWR vs MGNX Comparison
Open Charts ARWR vs MGNXBanner chart's image
Arrowhead Pharmaceuticals
Price$12.64
Change+$0.45 (+3.69%)
Volume$2.05K
Capitalization1.68B
MacroGenics
Price$1.23
Change+$0.01 (+0.82%)
Volume$12.68K
Capitalization80.76M
ARWR vs MGNX Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. MGNX commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and MGNX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (ARWR: $12.20 vs. MGNX: $1.22)
Brand notoriety: ARWR: Notable vs. MGNX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 114% vs. MGNX: 130%
Market capitalization -- ARWR: $1.68B vs. MGNX: $80.76M
ARWR [@Biotechnology] is valued at $1.68B. MGNX’s [@Biotechnology] market capitalization is $80.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileMGNX’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • MGNX’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than MGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while MGNX’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 5 bearish.
  • MGNX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MGNX is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а -17.14% price change this week, while MGNX (@Biotechnology) price change was -31.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.95%. For the same industry, the average monthly price growth was -7.12%, and the average quarterly price growth was -11.69%.

Reported Earning Dates

ARWR is expected to report earnings on May 08, 2025.

MGNX is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-4.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($1.68B) has a higher market cap than MGNX($80.8M). ARWR YTD gains are higher at: -35.080 vs. MGNX (-62.462). MGNX has higher annual earnings (EBITDA): -89.09M vs. ARWR (-580.69M). ARWR has more cash in the bank: 553M vs. MGNX (200M). MGNX has less debt than ARWR: MGNX (34.1M) vs ARWR (525M). MGNX has higher revenues than ARWR: MGNX (140M) vs ARWR (2.5M).
ARWRMGNXARWR / MGNX
Capitalization1.68B80.8M2,074%
EBITDA-580.69M-89.09M652%
Gain YTD-35.080-62.46256%
P/E RatioN/AN/A-
Revenue2.5M140M2%
Total Cash553M200M277%
Total Debt525M34.1M1,540%
FUNDAMENTALS RATINGS
ARWR vs MGNX: Fundamental Ratings
ARWR
MGNX
OUTLOOK RATING
1..100
5359
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9397
P/E GROWTH RATING
1..100
295
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MGNX's Valuation (81) in the Biotechnology industry is in the same range as ARWR (96). This means that MGNX’s stock grew similarly to ARWR’s over the last 12 months.

MGNX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that MGNX’s stock grew similarly to ARWR’s over the last 12 months.

MGNX's SMR Rating (98) in the Biotechnology industry is in the same range as ARWR (100). This means that MGNX’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (93) in the Biotechnology industry is in the same range as MGNX (97). This means that ARWR’s stock grew similarly to MGNX’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for MGNX (95). This means that ARWR’s stock grew significantly faster than MGNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRMGNX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 17 days ago
81%
Bullish Trend 22 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PNVAX40.86N/A
N/A
Putnam International Capital Opp A
VEUSX87.71N/A
N/A
Vanguard European Stock Admiral
PWDIX9.50N/A
N/A
Donoghue Forlines Dividend I
PEIRX22.41N/A
N/A
Federated Hermes International Equity R6
BRBCX14.01-0.03
-0.21%
BlackRock Tactical Opportunities Inv C

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-4.20%
DNLI - ARWR
56%
Loosely correlated
-9.60%
NTLA - ARWR
53%
Loosely correlated
-6.40%
BEAM - ARWR
50%
Loosely correlated
-9.70%
RGNX - ARWR
47%
Loosely correlated
-5.45%
CRNX - ARWR
47%
Loosely correlated
-8.71%
More

MGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with AMRN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then AMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGNX
1D Price
Change %
MGNX100%
-3.94%
AMRN - MGNX
44%
Loosely correlated
-1.36%
IOVA - MGNX
38%
Loosely correlated
-2.40%
ORMP - MGNX
34%
Loosely correlated
-0.47%
ATOS - MGNX
33%
Loosely correlated
-3.25%
ARWR - MGNX
33%
Poorly correlated
-4.20%
More